Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Multimodality tumor imaging targeting integrin alphavbeta3.

Cai W, Sam Gambhir S, Chen X.

Biotechniques. 2005 Dec;39(6 Suppl):S14-25. doi: 10.2144/000112091. Review.

2.

Imaging angiogenesis of genitourinary tumors.

Zee YK, O'Connor JP, Parker GJ, Jackson A, Clamp AR, Taylor MB, Clarke NW, Jayson GC.

Nat Rev Urol. 2010 Feb;7(2):69-82. doi: 10.1038/nrurol.2009.262. Epub 2010 Jan 19. Review.

PMID:
20084077
3.

Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).

Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, Hany T, Cescato-Wenger C, Brauchli P, Zünd M, Pestalozzi BC, Caspar C, Albrecht S, von Moos R, Ruhstaller T.

Onkologie. 2009 Dec;32(12):724-30. doi: 10.1159/000251842. Epub 2009 Nov 9.

PMID:
20016233
4.

Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, Okazawa H.

J Nucl Med. 2009 Dec;50(12):1948-53. doi: 10.2967/jnumed.109.069021. Epub 2009 Nov 12.

5.

Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging.

Kim S, Loevner LA, Quon H, Kilger A, Sherman E, Weinstein G, Chalian A, Poptani H.

AJNR Am J Neuroradiol. 2010 Feb;31(2):262-8. doi: 10.3174/ajnr.A1817. Epub 2009 Oct 1.

6.

Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.

Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, Lundgren S, Gribbestad IS.

NMR Biomed. 2010 Jan;23(1):56-65. doi: 10.1002/nbm.1426.

PMID:
19650073
7.

Cesarean section scar mimicking uterine malignant neoplasm at positron emission tomography/computed tomography.

Cheng YM, Ho CL, Chiu NT, Hsu KF.

J Minim Invasive Gynecol. 2009 May-Jun;16(3):372-4. doi: 10.1016/j.jmig.2009.02.005.

PMID:
19423072
8.

Fundamentals of quantitative dynamic contrast-enhanced MR imaging.

Paldino MJ, Barboriak DP.

Magn Reson Imaging Clin N Am. 2009 May;17(2):277-89. doi: 10.1016/j.mric.2009.01.007. Review.

PMID:
19406359
9.

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Wahl RL, Jacene H, Kasamon Y, Lodge MA.

J Nucl Med. 2009 May;50 Suppl 1:122S-50S. doi: 10.2967/jnumed.108.057307. Review.

10.

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review.

de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ.

J Nucl Med. 2009 May;50 Suppl 1:43S-54S. doi: 10.2967/jnumed.108.057224. Review.

11.

Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Hicks RJ.

J Nucl Med. 2009 May;50 Suppl 1:31S-42S. doi: 10.2967/jnumed.108.057216. Epub 2009 Apr 20. Review.

12.

Response to therapy in breast cancer.

Avril N, Sassen S, Roylance R.

J Nucl Med. 2009 May;50 Suppl 1:55S-63S. doi: 10.2967/jnumed.108.057240. Epub 2009 Apr 20. Review.

13.

18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.

Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.

J Nucl Med. 2009 May;50 Suppl 1:89S-96S. doi: 10.2967/jnumed.108.057232. Epub 2009 Apr 20. Review.

14.

Assessing tumor response to therapy.

Weber WA.

J Nucl Med. 2009 May;50 Suppl 1:1S-10S. doi: 10.2967/jnumed.108.057174. Epub 2009 Apr 20. Review.

15.

Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers.

Liu Z, Liu S, Wang F, Liu S, Chen X.

Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1296-307. doi: 10.1007/s00259-009-1112-2. Epub 2009 Mar 19.

PMID:
19296102
16.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
17.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
18.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.

Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

PMID:
19097774
19.

Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.

Heinrich S, Schäfer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA.

Ann Surg. 2008 Dec;248(6):1014-22. doi: 10.1097/SLA.0b013e318190a6da.

PMID:
19092346
20.

[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.

Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, Lee DH, Suh C, Lee JS, Kim SW.

Clin Cancer Res. 2008 Nov 15;14(22):7423-9. doi: 10.1158/1078-0432.CCR-08-0312.

Supplemental Content

Support Center